TICKERNERD
Menu
PHIOPHIOHealthcare · Biotechnology

PHIO Stock Forecast: Phio Pharmaceuticals Corp. Price Predictions for 2026-2027

Last close, 13 Nov 2026
$0.77
−5.15% on the day

The 1 Wall Street analysts covering Phio Pharmaceuticals Corp. hold a median 12-month price target of $14 — +1717.7% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 28 of 100 as at 13 Nov 2026 — in the lower half. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$9.2M
Ticker Nerd rank
28/ 100
Median analyst target
$14
Analysts covering
1
Revenue$0.0
Operating income−$4.3M
Net income−$4.1M
Free cash flow−$4.0M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−3.8%
1M
−17.6%
YTD
−26.6%
1Y
−46.1%
From 52W high
−53.3%
From 52W low
0.0%
$0.77
$1.65
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

PHIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Phio Pharmaceuticals Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 13 Nov 2026
28/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Accruals
81
Revisions
48
Volatility
48
Quality
38
Issuance
25
Growth
25
Value
14
Momentum
9

Size (91): Smaller than most of the companies we track.

Momentum (9): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

PHIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on PHIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.00$5.00$10.00$15.00Jan 26Apr 26Jul 26Oct 26PHIOHigh $14Median $14Low $14

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $14Median $14High $14

The green dot is the last close — the median target sits +1717.7% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
26 Aug 2026HC Wainwright & Co.ReiteratesBuy$14
10 Feb 2026HC Wainwright & Co.ReiteratesBuy$14
10 Feb 2026HC Wainwright & Co.ReiteratesBuy—
15 Aug 2025HC Wainwright & Co.ReiteratesBuy—
25 June 2025HC Wainwright & Co.ReiteratesBuy—
5 June 2025HC Wainwright & Co.AssumesBuy$14
8 Apr 2025HC Wainwright & Co.ReiteratesBuy—
19 Feb 2025HC Wainwright & Co.ReiteratesBuy—
14 May 2024HC Wainwright & Co.ReiteratesBuy—
6 Feb 2024HC Wainwright & Co.MaintainsBuy—
16 Aug 2023HC Wainwright & Co.ReiteratesBuy—
14 June 2021HC Wainwright & Co.MaintainsBuy$4.00 → $6.00
25 Nov 2020HC Wainwright & Co.InitiatesBuy—
5 Aug 2020HC Wainwright & Co.InitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

PHIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

PHIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 13 Nov 2026, Phio Pharmaceuticals Corp. returned −46.1% against +13.4% for the S&P 500, dividends included.

PHIO vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120Jan 26Apr 26Jul 26Oct 26PHIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

PHIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
2
Fundamentals

Phio Pharmaceuticals Corp. (PHIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.0×

Cheaper than 75% of US stocks

Price / sales
—
Price / book
0.4×

Cheaper than 83% of US stocks

EV / EBITDA
0.3×

Cheaper than 61% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−113.7%

Higher than 12% of US stocks

Return on assets
−65.8%

Higher than 5% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Phio Pharmaceuticals Corp. (PHIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Phio Pharmaceuticals Corp. has a market value of $9.2M and an enterprise value of −$3.7M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$12.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$12.2M.

  • Shares outstanding: 11.6M.

  • Trailing P/E: 0.0×; forward P/E: −1.3× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Phio Pharmaceuticals Corp. employs 6 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 14 Nov 2026

Data provided by Twelve Data

Peers

PHIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
PHIOPhio Pharmaceuticals Corp.$9.2M28
AEONAEON Biopharma, Inc.$9.0M45
INABIN8bio, Inc.$8.9M31
LEXXLexaria Bioscience Corp.$9.4M19
MTVAMetaVia, Inc.$8.6M17
MBRXMoleculin Biotech, Inc.$8.3M21
CALCCalciMedica, Inc.$8.3M37

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Phio Pharmaceuticals Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest PHIO news & analysis

Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)

Newsfile Corp · 6 Nov 2026positive

Phio Pharmaceuticals announced it was invited to give an oral presentation of clinical data from its Phase 1b trial at the 41st Annual Meeting of the Society for Immunotherapy of Cancer, held November 6–8, 2026, in Phoenix.

Why it matters — The presentation provides PHIO watchers an opportunity to learn about clinical data from the company's Phase 1b trial.

Phio Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Update as It Advances PH-762 Toward Phase 2b Study Initiation

Newsfile Corp · 5 Nov 2026positive

Phio Pharmaceuticals reported third-quarter 2026 financial results and a business update, saying PH-762 reached milestones including commercial-scale cGMP manufacturing completion, treatment in a long-term toxicology study, and submission of key regulatory documents to the FDA. The company said these steps advance the program toward Phase 2b study initiation.

Why it matters — The update outlines manufacturing, toxicology, and regulatory progress in PHIO’s PH-762 development program ahead of a planned Phase 2b study.

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

Newsfile Corp · 19 Oct 2026neutral

Phio Pharmaceuticals announced that CEO and Chairman Robert Bitterman will present an overview of its INTASYL siRNA platform, including lead clinical candidate PH-762, at a Renmark Financial Communications virtual non-deal roadshow on October 20, 2026.

Why it matters — The presentation will provide PHIO watchers with an opportunity to hear about the company’s therapeutic platform and lead candidate.

Phio Pharmaceuticals to Present at the National Investment Banking Association (NIBA) 153rd Conference

Newsfile Corp · 5 Oct 2026neutral

Phio Pharmaceuticals announced it will present at the National Investment Banking Association's 153rd Conference on October 6-7, 2026, in Fort Lauderdale, Florida. CEO Robert Bitterman will present the company's INTASYL siRNA therapeutic platform, its differentiated delivery approach, and its strategic direction, including a development update on the lead PH-762 program in cutaneous squamous cell carcinoma.

Why it matters — The presentation offers PHIO watchers a scheduled opportunity to hear directly from management about the company's lead PH-762 program and strategic direction at a national investor event.

Phio Pharmaceuticals to Present Clinical Development Update and Upcoming Catalysts at Life Sciences Future 2026 Conference

Newsfile Corp · 23 Sept 2026neutral

Phio Pharmaceuticals announced it will present at the Life Sciences Future 2026 Conference on September 30 to October 1, 2026, in King of Prussia, Pennsylvania. CEO Robert Bitterman will provide an update on the completed Phase 1b clinical study of PH-762 in cutaneous squamous cell carcinoma and outline planned next steps to advance the program.

Why it matters — PHIO watchers would care because the presentation provides an update on the completed Phase 1b study of its lead candidate PH-762 and signals the program's path toward its next stage of clinical development.

FAQ

Frequently asked questions about PHIO stock

What is the PHIO stock price forecast for 2026-2027?

The 1 Wall Street analysts covering Phio Pharmaceuticals Corp. have a median 12-month price target of $14, with estimates ranging from $14 to $14. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is PHIO stock a buy right now?

Of the 1 analysts covering Phio Pharmaceuticals Corp., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Phio Pharmaceuticals Corp. 28 out of 100 across roughly 4,600 US stocks as at 13 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank PHIO?

As at 13 Nov 2026, Phio Pharmaceuticals Corp. ranks 28 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

Will PHIO stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +1717.7% from the last close, and Ticker Nerd's factor model ranks Phio Pharmaceuticals Corp. 28 out of 100 as at 13 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the PHIO stock forecast for 2030?

No analyst covering Phio Pharmaceuticals Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PHIO are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $14 to $14 over the next 12 months.

How has PHIO stock performed over the past year?

Phio Pharmaceuticals Corp. returned -46.1% over the 12 months to 13 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Phio Pharmaceuticals Corp. do?

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL RNA interference platform.

What is the latest news on PHIO?

The most recent item we track (Newsfile Corp, 6 Nov 2026): "Phio Pharmaceuticals Announces Invitation for Oral Presentation at 41st Annual SITC Meeting (Society for Immunotherapy of Cancer)". Phio Pharmaceuticals announced it was invited to give an oral presentation of clinical data from its Phase 1b trial at the 41st Annual Meeting of the Society for Immunotherapy of Cancer, held November 6–8, 2026, in Phoenix.

Company

About Phio Pharmaceuticals Corp.

Phio Pharmaceuticals Corp. is a clinical-stage biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL RNA interference platform. The company’s current work centers on gene-silencing candidates designed to help immune cells better recognize and attack tumor cells, with a primary emphasis on cancer research and treatment applications. Its lead programs include PH-762, which targets PD-1 expression in ongoing clinical studies, and PH-894, which is being evaluated in preclinical research for selective BRD4 silencing. Phio Pharmaceuticals Corp. operates in the biotechnology sector and plays a role in advancing RNAi-based approaches for oncology, particularly in areas such as skin cancers and other solid tumors.

CEO Mr. Robert J. Bitterman · 6 employees · United States · https://phiopharma.com